# Hongtao Capital

> Hongtao Capital is a VC fund in Shenzhen backing Biopharma, Biotechnology and Retail. See 4 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Shenzhen, China
- Total investments: 4
- Last investment: Aug 2025
- Lead investor: 75%
- Last updated: Aug 2026

Hongtao Capital is a VC fund in Shenzhen focused on Biopharma and Biotechnology. Hongtao Capitals a private equity fund management firm that focuses on investments In artificial intelligence, semiconductors, and biomedicine. The firm was established in Shenzhen, Guangdong.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biopharma | 2 | 50% |
| Biotechnology | 2 | 50% |
| Retail | 1 | 25% |
| Medical | 1 | 25% |
| Wholesale | 1 | 25% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Angel | 2 | 50% |
| Seed | 1 | 25% |
| Series D | 1 | 25% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 2 | 50% |
| United States | 1 | 25% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Xianong Cold Chain Technology | Xianong Cold Chain Technology specializes in the retail service of aquatic products. |  | Angel | Aug 19, 2025 |  |
| Hongxin Biology | Hongxin Bio is an mRNA drug developer, focusing on nucleic acid drug delivery and RNA drug development. |  | Seed | Jan 16, 2024 |  |
| Hongxin Biology | Hongxin Bio is an mRNA drug developer, focusing on nucleic acid drug delivery and RNA drug development. |  | Angel | Dec 30, 2022 |  |
| Sirnaomics | Sirnaomics is a biopharmaceutical company developing therapeutics for critical human diseases by using RNA interference technology. | $105M | Series D | Oct 23, 2020 |  |

4 of 4 investments shown.

## Co-investors
- [Haiyuan Capital](https://shizune.co/investors/profile/goldport-capital) — VC Fund, 2 deals together
- [Alpha Win Capital](https://shizune.co/investors/profile/alpha-win-capital) — VC Fund, 1 deal together
- Hinova Pharma — VC Fund, 1 deal together
- [Longmen Capital](https://shizune.co/investors/profile/longmen-capital) — VC Fund, 1 deal together
- Nanling Fund — VC Fund, 1 deal together
- [RiverHead Capital](https://shizune.co/investors/profile/river-head-capital) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [LVX Ventures](https://shizune.co/investors/profile/letsventure) — VC Fund
- [ZhenFund](https://shizune.co/investors/profile/zhenfund) — VC Fund
- [IAN Group](https://shizune.co/investors/profile/indian-angel-network) — VC Fund

## FAQ

### What does Hongtao Capital invest in?

Hongtao Capital invests primarily in Biopharma, Biotechnology and Retail startups, most often at Angel and Seed stage. Most of the 4 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Hongtao Capital last invest?

The most recent investment recorded for Hongtao Capital closed in Aug 2025. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co